A genetically engineered vector vaccine is a type of vaccine that uses a viral vector that has been genetically modified to carry and express genes encoding antigens from a pathogen, such as a virus or bacterium. This approach is part of the broader field of genetic engineering in vaccinology and is designed to stimulate an immune response against the target pathogen.
The global Genetically Engineered Vector Vaccine market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淕enetically Engineered Vector Vaccine Industry Forecast鈥� looks at past sales and reviews total world Genetically Engineered Vector Vaccine sales in 2023, providing a comprehensive analysis by region and market sector of projected Genetically Engineered Vector Vaccine sales for 2024 through 2030. With Genetically Engineered Vector Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genetically Engineered Vector Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Genetically Engineered Vector Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Genetically Engineered Vector Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Genetically Engineered Vector Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genetically Engineered Vector Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genetically Engineered Vector Vaccine.
United States market for Genetically Engineered Vector Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Genetically Engineered Vector Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Genetically Engineered Vector Vaccine is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Genetically Engineered Vector Vaccine players cover Pfizer, Merck, GSK, Wantai Biotechnology and Watson Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Genetically Engineered Vector Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Viral Vector Vaccine
Plasmid Vector Vaccine
VLPV
RNA Vaccine
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Merck
GSK
Wantai Biotechnology
Watson Bio
Bharat Biotech
Sanofi
Zoties
Elanco
Boehringer Ingelheim
Indian Immunologicals
Zhongmu Industrial Co., Ltd.
Qingdao Yibang Bioengineering Co., Ltd.
Jinyu Biotechnology
Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences
Tianjin Ruipu Biotechnology
Kyoto Biken Laboratories
FATRO
Ceva Sant茅 Animale
Pleco
Wuhan Huisheng Biotechnology
Jinhe Biotechnology
Shenlian Biotechnology
Azure Creatures
Key Questions Addressed in this Report
What is the 10-year outlook for the global Genetically Engineered Vector Vaccine market?
What factors are driving Genetically Engineered Vector Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Genetically Engineered Vector Vaccine market opportunities vary by end market size?
How does Genetically Engineered Vector Vaccine break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Genetically Engineered Vector Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Genetically Engineered Vector Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Genetically Engineered Vector Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Genetically Engineered Vector Vaccine Segment by Type
2.2.1 Viral Vector Vaccine
2.2.2 Plasmid Vector Vaccine
2.2.3 VLPV
2.2.4 RNA Vaccine
2.3 Genetically Engineered Vector Vaccine Sales by Type
2.3.1 Global Genetically Engineered Vector Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Genetically Engineered Vector Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Genetically Engineered Vector Vaccine Sale Price by Type (2019-2024)
2.4 Genetically Engineered Vector Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Genetically Engineered Vector Vaccine Sales by Application
2.5.1 Global Genetically Engineered Vector Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Genetically Engineered Vector Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Genetically Engineered Vector Vaccine Sale Price by Application (2019-2024)
3 Global Genetically Engineered Vector Vaccine by Company
3.1 Global Genetically Engineered Vector Vaccine Breakdown Data by Company
3.1.1 Global Genetically Engineered Vector Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Genetically Engineered Vector Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Genetically Engineered Vector Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Genetically Engineered Vector Vaccine Revenue by Company (2019-2024)
3.2.2 Global Genetically Engineered Vector Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Genetically Engineered Vector Vaccine Sale Price by Company
3.4 Key Manufacturers Genetically Engineered Vector Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Genetically Engineered Vector Vaccine Product Location Distribution
3.4.2 Players Genetically Engineered Vector Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Genetically Engineered Vector Vaccine by Geographic Region
4.1 World Historic Genetically Engineered Vector Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Genetically Engineered Vector Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Genetically Engineered Vector Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Genetically Engineered Vector Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Genetically Engineered Vector Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Genetically Engineered Vector Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Genetically Engineered Vector Vaccine Sales Growth
4.4 APAC Genetically Engineered Vector Vaccine Sales Growth
4.5 Europe Genetically Engineered Vector Vaccine Sales Growth
4.6 Middle East & Africa Genetically Engineered Vector Vaccine Sales Growth
5 Americas
5.1 Americas Genetically Engineered Vector Vaccine Sales by Country
5.1.1 Americas Genetically Engineered Vector Vaccine Sales by Country (2019-2024)
5.1.2 Americas Genetically Engineered Vector Vaccine Revenue by Country (2019-2024)
5.2 Americas Genetically Engineered Vector Vaccine Sales by Type
5.3 Americas Genetically Engineered Vector Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genetically Engineered Vector Vaccine Sales by Region
6.1.1 APAC Genetically Engineered Vector Vaccine Sales by Region (2019-2024)
6.1.2 APAC Genetically Engineered Vector Vaccine Revenue by Region (2019-2024)
6.2 APAC Genetically Engineered Vector Vaccine Sales by Type
6.3 APAC Genetically Engineered Vector Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Genetically Engineered Vector Vaccine by Country
7.1.1 Europe Genetically Engineered Vector Vaccine Sales by Country (2019-2024)
7.1.2 Europe Genetically Engineered Vector Vaccine Revenue by Country (2019-2024)
7.2 Europe Genetically Engineered Vector Vaccine Sales by Type
7.3 Europe Genetically Engineered Vector Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Genetically Engineered Vector Vaccine by Country
8.1.1 Middle East & Africa Genetically Engineered Vector Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Genetically Engineered Vector Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Genetically Engineered Vector Vaccine Sales by Type
8.3 Middle East & Africa Genetically Engineered Vector Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Genetically Engineered Vector Vaccine
10.3 Manufacturing Process Analysis of Genetically Engineered Vector Vaccine
10.4 Industry Chain Structure of Genetically Engineered Vector Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Genetically Engineered Vector Vaccine Distributors
11.3 Genetically Engineered Vector Vaccine Customer
12 World Forecast Review for Genetically Engineered Vector Vaccine by Geographic Region
12.1 Global Genetically Engineered Vector Vaccine Market Size Forecast by Region
12.1.1 Global Genetically Engineered Vector Vaccine Forecast by Region (2025-2030)
12.1.2 Global Genetically Engineered Vector Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Genetically Engineered Vector Vaccine Forecast by Type
12.7 Global Genetically Engineered Vector Vaccine Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.2.3 Merck Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.3.3 GSK Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Wantai Biotechnology
13.4.1 Wantai Biotechnology Company Information
13.4.2 Wantai Biotechnology Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.4.3 Wantai Biotechnology Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Wantai Biotechnology Main Business Overview
13.4.5 Wantai Biotechnology Latest Developments
13.5 Watson Bio
13.5.1 Watson Bio Company Information
13.5.2 Watson Bio Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.5.3 Watson Bio Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Watson Bio Main Business Overview
13.5.5 Watson Bio Latest Developments
13.6 Bharat Biotech
13.6.1 Bharat Biotech Company Information
13.6.2 Bharat Biotech Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.6.3 Bharat Biotech Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bharat Biotech Main Business Overview
13.6.5 Bharat Biotech Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.7.3 Sanofi Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Zoties
13.8.1 Zoties Company Information
13.8.2 Zoties Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.8.3 Zoties Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Zoties Main Business Overview
13.8.5 Zoties Latest Developments
13.9 Elanco
13.9.1 Elanco Company Information
13.9.2 Elanco Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.9.3 Elanco Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Elanco Main Business Overview
13.9.5 Elanco Latest Developments
13.10 Boehringer Ingelheim
13.10.1 Boehringer Ingelheim Company Information
13.10.2 Boehringer Ingelheim Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.10.3 Boehringer Ingelheim Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Boehringer Ingelheim Main Business Overview
13.10.5 Boehringer Ingelheim Latest Developments
13.11 Indian Immunologicals
13.11.1 Indian Immunologicals Company Information
13.11.2 Indian Immunologicals Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.11.3 Indian Immunologicals Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Indian Immunologicals Main Business Overview
13.11.5 Indian Immunologicals Latest Developments
13.12 Zhongmu Industrial Co., Ltd.
13.12.1 Zhongmu Industrial Co., Ltd. Company Information
13.12.2 Zhongmu Industrial Co., Ltd. Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.12.3 Zhongmu Industrial Co., Ltd. Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zhongmu Industrial Co., Ltd. Main Business Overview
13.12.5 Zhongmu Industrial Co., Ltd. Latest Developments
13.13 Qingdao Yibang Bioengineering Co., Ltd.
13.13.1 Qingdao Yibang Bioengineering Co., Ltd. Company Information
13.13.2 Qingdao Yibang Bioengineering Co., Ltd. Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.13.3 Qingdao Yibang Bioengineering Co., Ltd. Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Qingdao Yibang Bioengineering Co., Ltd. Main Business Overview
13.13.5 Qingdao Yibang Bioengineering Co., Ltd. Latest Developments
13.14 Jinyu Biotechnology
13.14.1 Jinyu Biotechnology Company Information
13.14.2 Jinyu Biotechnology Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.14.3 Jinyu Biotechnology Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Jinyu Biotechnology Main Business Overview
13.14.5 Jinyu Biotechnology Latest Developments
13.15 Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences
13.15.1 Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences Company Information
13.15.2 Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.15.3 Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences Main Business Overview
13.15.5 Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences Latest Developments
13.16 Tianjin Ruipu Biotechnology
13.16.1 Tianjin Ruipu Biotechnology Company Information
13.16.2 Tianjin Ruipu Biotechnology Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.16.3 Tianjin Ruipu Biotechnology Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Tianjin Ruipu Biotechnology Main Business Overview
13.16.5 Tianjin Ruipu Biotechnology Latest Developments
13.17 Kyoto Biken Laboratories
13.17.1 Kyoto Biken Laboratories Company Information
13.17.2 Kyoto Biken Laboratories Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.17.3 Kyoto Biken Laboratories Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Kyoto Biken Laboratories Main Business Overview
13.17.5 Kyoto Biken Laboratories Latest Developments
13.18 FATRO
13.18.1 FATRO Company Information
13.18.2 FATRO Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.18.3 FATRO Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 FATRO Main Business Overview
13.18.5 FATRO Latest Developments
13.19 Ceva Sant茅 Animale
13.19.1 Ceva Sant茅 Animale Company Information
13.19.2 Ceva Sant茅 Animale Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.19.3 Ceva Sant茅 Animale Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Ceva Sant茅 Animale Main Business Overview
13.19.5 Ceva Sant茅 Animale Latest Developments
13.20 Pleco
13.20.1 Pleco Company Information
13.20.2 Pleco Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.20.3 Pleco Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Pleco Main Business Overview
13.20.5 Pleco Latest Developments
13.21 Wuhan Huisheng Biotechnology
13.21.1 Wuhan Huisheng Biotechnology Company Information
13.21.2 Wuhan Huisheng Biotechnology Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.21.3 Wuhan Huisheng Biotechnology Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Wuhan Huisheng Biotechnology Main Business Overview
13.21.5 Wuhan Huisheng Biotechnology Latest Developments
13.22 Jinhe Biotechnology
13.22.1 Jinhe Biotechnology Company Information
13.22.2 Jinhe Biotechnology Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.22.3 Jinhe Biotechnology Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 Jinhe Biotechnology Main Business Overview
13.22.5 Jinhe Biotechnology Latest Developments
13.23 Shenlian Biotechnology
13.23.1 Shenlian Biotechnology Company Information
13.23.2 Shenlian Biotechnology Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.23.3 Shenlian Biotechnology Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.23.4 Shenlian Biotechnology Main Business Overview
13.23.5 Shenlian Biotechnology Latest Developments
13.24 Azure Creatures
13.24.1 Azure Creatures Company Information
13.24.2 Azure Creatures Genetically Engineered Vector Vaccine Product Portfolios and Specifications
13.24.3 Azure Creatures Genetically Engineered Vector Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.24.4 Azure Creatures Main Business Overview
13.24.5 Azure Creatures Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
